Back to Feed
ClinicalTrials.gov|Clinical Trial
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Abstract
The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS). Phase: PHASE3 Status: ACTIVE_NOT_RECRUITING Conditions: Multiple Myeloma Interventions: Bortezomib; Dexamethasone; Lenalidomide; Cilta-cel; Cyclophosphamide; Fludarabine
Keywords
Multiple Myeloma